首页|人免疫球蛋白联合双歧杆菌三联活菌治疗ABO血型不合性溶血新生儿的效果

人免疫球蛋白联合双歧杆菌三联活菌治疗ABO血型不合性溶血新生儿的效果

扫码查看
目的:探讨人免疫球蛋白联合双歧杆菌三联活菌治疗ABO血型不合性溶血新生儿的效果.方法:收集2019年7月—2024年7月我院收治的106例新生儿ABO-HDN的临床资料,根据治疗方式分为实验组57例和对照组49例,对照组予以人免疫球蛋白治疗,实验组在对照组基础上予以双歧杆菌三联活菌治疗.比较两组光疗时间、黄疸消退时间、血红蛋白(Hb)及总胆红素(TSB)水平变化、并发症及神经系统发育预后.结果:两组治疗后Hb、TSB水平均较治疗前改善,两组Hb水平比较,差异无统计学意义(P>0.05),实验组治疗后TSB水平低于对照组,且TSB日均下降幅度大于对照组,差异有统计学意义(P<0.05).两组光疗时间比较,差异无统计学意义(P>0.05),实验组皮肤黄染消失时间短于对照组,差异有统计学意义(P<0.05).实验组腹泻发生率低于对照组(P<0.05).两组神经系统不良预后比较,差异无统计学意义(P>0.05).结论:双歧杆菌三联活菌辅助人免疫球蛋白治疗新生儿ABO血型不合性溶血,可促进黄疸消退,减少腹泻发生,具有较好的获益.
Effect of Human Immunoglobulin Combined with Bifid. Triple Viable in the Treatment of ABO Blood Group Incompatibility Hemolytic Neonates
Objective:To investigate the effect of human immunoglobulin combined with bifid.triple viable in the treatment of neonates with hemolysis caused by ABO blood group incompatibility. Methods:The clinical data of 106 cases of neonatal ABO-HDN admitted to our hospital from July 2019 to July 2024 were collected. According to the treatment methods,they were divided into experimental group (57 cases) and control group (49 cases). The control group was treated with human immunoglobulin,and the experimental group was treated with bifid.triple viable on the basis of the control group. The phototherapy time,jaundice regression time,hemoglobin (Hb) and total bilirubin (TSB) levels,complications and neurological development prognosis were compared between the two groups. Results:After treatment,the levels of Hb and TSB in the two groups were improved compared with those before treatment,but there was no significant difference in the level of Hb between the two groups after treatment (P>0.05),while the level of TSB in the experimental group was lower than that in the control group after treatment,and the daily decrease of TSB was greater than that in the control group,the difference was statistically significant (P<0.05). The disappearance time of skin yellow staining in the experimental group was shorter than that in the control group,the difference was statistically significant (P<0.05). There was no significant difference in phototherapy time between the two groups (P>0.05). The disappearance time of skin yellow staining in the experimental group was shorter than that in the control group,and the difference was statistically significant (P<0.05). The incidence of diarrhea in the experimental group was lower than that in the control group (P<0.05). There was no significant difference in the poor prognosis of nervous system between the two groups (P>0.05). Conclusion:Bifid.triple viable assisted human immunoglobulin in the treatment of neonatal ABO blood group incompatibility hemolysis can promote the regression of jaundice and reduce the occurrence of diarrhea,with good benefits.

Haemolytic disease of the newbornHuman immunoglobulinABO blood group incompatibilityBifid. Triple viable

郭翅、张光林、陈少华

展开 >

三明市第二医院儿科,福建三明 366000

新生儿溶血病 人免疫球蛋白 ABO血型不合 双歧杆菌三联活菌

2024

中国药物滥用防治杂志
中国药物滥用防治协会 军事医学科学院毒物药物研究所

中国药物滥用防治杂志

影响因子:0.584
ISSN:1006-902X
年,卷(期):2024.30(11)